.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,162,802

« Back to Dashboard
Patent 6,162,802 protects LOTREL and is included in one NDA. There have been two Paragraph IV challenges on Lotrel. There are two tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Summary for Patent: 6,162,802

Title: Synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions therefor
Abstract:A method for the treatment of a variety of cardiovascular disorders and related conditions in a mammal having at least one such disorder or condition is disclosed comprising treating the mammal with cotherapy comprising benazepril and amlodipine or pharmaceutically acceptable salts of either or both. Combination formulations of benazepril and amlodipine for use in the method are also disclosed.
Inventor(s): Papa; Joseph (Allschwil, CH), Henis; Marc M. J. (Randolph, NJ)
Assignee:
Application Number:07/848,816
Patent Claim Types:
see list of patent claims
Use; Dosage form; Formulation; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis
LOTREL
amlodipine besylate; benazepril hydrochloride
CAPSULE;ORAL020364-002Mar 3, 1995RXNo6,162,802► subscribe TREATMENT OF CARDIOVASCULAR DISORDERS
Novartis
LOTREL
amlodipine besylate; benazepril hydrochloride
CAPSULE;ORAL020364-003Mar 3, 1995RXNo6,162,802► subscribe TREATMENT OF CARDIOVASCULAR DISORDERS
Novartis
LOTREL
amlodipine besylate; benazepril hydrochloride
CAPSULE;ORAL020364-004Mar 3, 1995RXNo6,162,802► subscribe TREATMENT OF CARDIOVASCULAR DISORDERS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc